Warrant Amendment Agreement, dated February 14, 2019

 

 

 

Reference is hereby made to those common stock purchase warrants set forth in Exhibit A hereto (each a “Warrant,” and together the “Warrants”). Capitalized terms used but not otherwise defined herein shall have the meaning ascribed to such terms in each of the Warrants.

 

In connection with, and as partial consideration for, the sale and issuance of certain Senior Convertible Promissory Notes by AzurRx BioPharma, Inc. (the “Company”) to certain investor signatories to that certain Note Purchase Agreement, dated February 14, 2019 (“NPA”), the Company hereby agrees to amend each Warrant to decrease the Exercise Price thereof to $1.50 per share (the “Warrant Amendment”). This agreement shall only serve to amend the Exercise Price of each of the Warrants set forth on Exhibit A attached hereto, and all other terms of the Warrants shall remain in full force and effect.

In furtherance of the foregoing, the Company shall prepare, execute and deliver to the holder of each Warrant a formal amendment to each Warrant to effect the agreement of the Company set forth herein, on or before ten (10) business days from the date hereof.

Very truly yours,

AZURRX BIOPHARMA, INC.

By: /s/ Johan M. Spoor

Name: Johan M. Spoor

Title: Chief Executive Officer